Preferred Label : MVA-EBNA1/LMP2 Vaccine;
NCIt definition : A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral
vector encoding the gene for the CD4 epitope-rich C-terminal domain of the Epstein
Barr Virus (EBV) antigen EBNA1 and fused to the full-length of the EBV-associated
antigen latent membrane protein 2 (LMP2), with potential immunostimulatory and antineoplastic
activities. Upon administration, MVA EBNA1/LMP2 vaccine may elicit a cytotoxic T-cell
immune response against cancer cells expressing EBNA1 and LMP2. Multi-antigen vaccine
therapy may be more efficacious than single-antigen therapy vaccine therapy. EBNA1,
a sequence-specific DNA binding protein, plays an important role in EBV episomal genome
maintenance and gene transactivation.;
NCI Metathesaurus CUI : CL421473;
Origin ID : C91076;
UMLS CUI : C2984017;
Semantic type(s)
- concept_is_in_subset
